Multimodal Management of Early-Stage NSCLC: EGFR-Targeted Therapy in Perioperative Settings

Realizing the Promise of Perioperative Immunotherapy in Resectable NSCLCПодробнее

Drs. Sepesi & Cascone discuss EGFR-targeted therapy in early-stage NSCLC: https://bit.ly/3oZllfoПодробнее

Adjuvant EGFR-Targeted Therapy as a Game Changer in Multimodal NSCLC ManagementПодробнее

Precision Oncology in Early-Stage Lung Cancer, With Adjuvant EGFR-Targeted Therapy Leading the WayПодробнее

Time for Even More Precision in Testing and Treatment of EGFR-Mutated NSCLCПодробнее

New Milestones and Changing Standards of Care in Early EGFR-Mutated NSCLCПодробнее

Can the Addition of Immunotherapy to Multimodal Management of Stage I-III NSCLC Improve Outcomes?Подробнее

How to Integrate Perioperative Immunotherapy Into Multimodal Treatment Plans in Resectable NSCLCПодробнее

EGFR-Targeted Therapy for Early-Stage NSCLC: What Thoracic Surgeons Need to KnowПодробнее

Marking New Milestones With Immunotherapy in Locally Advanced and Early Lung CancerПодробнее

Drs. Altorki & Spicer discuss #NSCLC #Immunotherapy at #ThoracicSummit2022 - https://bit.ly/3BXcsbVПодробнее

Implications of Early Molecular Testing on Perioperative Therapy in Early Stage NSCLCПодробнее

RET+ NSCLC Treatment Options - 2022 Program: Targeted Therapies ForumПодробнее

Perioperative Therapy in Early Stage NSCLC-Implications for Molecular TestingПодробнее

ILCN Multidisciplinary Forum: Understanding Treatment Options and Resistance in EGFR-positive NSCLCПодробнее

The role of surgery in early-stage NSCLC management | Jessica DoningtonПодробнее

Has Immunotherapy Brought Us to an Inflection Point in the Management of Stage I-III NSCLC?Подробнее

Neoadjuvant, Adjuvant, or Both: Individualized Perioperative Immunotherapy in Resectable NSCLCПодробнее

Marking New Milestones With Immunotherapy in Locally Advanced and Early Lung CancerПодробнее